secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbCellera Biologics Inc. (ABCL)
CIK:        0001703057
Form:       8-K
Filed at:   2022-07-19T23:59:59+00:00
Accession:  0001564590-22-025922
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbCellera CBO Neil Berkley departs; separation deal includes salary continuation, equity acceleration
--------------------------------------------------------------------------------

- Neil Berkley left as Chief Business Officer effective June 29, 2022.
- Receives 12 months base salary ($450,000/yr) paid over 12 months, plus $173,710 cash payment.
- AbCellera accelerates vesting of 17,500 RSUs; shares issued on Aug 11, 2022 after trading restriction.
- Company pays COBRA premiums through July 1, 2023 or earlier if new job obtained.
- Separation agreement includes non-disparagement, non-solicitation, and confidentiality covenants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703057/000156459022025922/0001564590-22-025922-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703057/000156459022025922/abcl-8k_20220709.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-025922

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer